Main > ONCOLOGY (**) > Liver Cancer *** > Treatment. > CN. I. HCC>TREAT.>PD-1 Binding MAb+

---

CN. I. HCC>TREAT.>PD-1 Binding MAb+'s subsections
(*) CN Approval Date: 2021. 06.27.
+Inj.+BevacizuMAb Biosimilar
Company
Generic Name: Sintilimab
Patent>Assignee; Claims; No.; Etc
Patent>Total USA No.: 3
Patent>UpDate: 2021. 06.29.
PD: Programmed cell Death
PR Web-Site
RTM

CN. I. HCC>TREAT.>PD-1 Binding MAb+'s products
This section has no products